51 results
Keyword Enspryng Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-001625-PIP02-21, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 03/12/2021, Last updated: 06/03/2023, Compliance check: XInvented name Enspryng Active substance satralizumab … Enspryng Enspryng satralizumab satralizumab … -
List item
Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody (satralizumab) for: Treatment of neuromyelitis optica spectrum disorders
Date of designation: 27/06/2016, Positive, Last updated: 30/06/2021been authorised in the EU as Enspryng since 24 June 2021. What … Overview'. orphan designation of Enspryng (humanised anti-IL-6 receptor … Enspryng Enspryng satralizumab Humanised … -
List item
Human medicine European public assessment report (EPAR): Enspryng
satralizumab, Neuromyelitis Optica
Date of authorisation: 24/06/2021,
, Revision: 2, Authorised, Last updated: 24/03/2023
Enspryng Nervous System Diseases Autoimmune … orised satralizumab Overview Enspryng is a medicine used to treat … AQP4). NMOSD is rare, and Enspryng was designated an ‘ A medicine … -
List item
News: New treatment for rare autoimmune disease of nerve cells
CHMP, Last updated: 23/04/2021the European Union (EU) for Enspryng (satralizumab) for the treatment … 100,000 people in the EU. Enspryng works by reducing and preventing … active substance contained in Enspryng, is an antibody designed to … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021
CHMP, Last updated: 23/04/2021Enspryng … -
List item
Human medicine European public assessment report (EPAR): Uplizna
Inebilizumab, Neuromyelitis Optica
Date of authorisation: 25/04/2022,
, Revision: 2, Authorised, Last updated: 21/04/2023
-
List item
Orphan designation: zanubrutinib for: Treatment of marginal zone lymphoma
Date of designation: 20/05/2021, Withdrawn, Last updated: 05/01/2023 -
List item
Orphan designation: Adeno-associated virus serotype 9 expressing the cDNA for human MECP2 for: Treatment of Rett syndrome
Date of designation: 20/05/2021, Withdrawn, Last updated: 30/03/2022 -
List item
Orphan designation: begelomab for: Treatment of dermatomyositis
Date of designation: 20/05/2021, Positive, Last updated: 16/03/2022 -
List item
Orphan designation: Macitentan for: Treatment of functional single ventricle congenital heart disease
Date of designation: 20/05/2021, Positive, Last updated: 16/03/2022 -
List item
Orphan designation: Eflornithine for: Treatment of neuroblastoma
Date of designation: 20/05/2021, Positive, Last updated: 17/03/2022 -
List item
Orphan designation: Elamipretide for: Treatment of Barth syndrome
Date of designation: 20/05/2021, Positive, Last updated: 17/03/2022 -
List item
Orphan designation: Human IgG1 monoclonal antibody against alpha-synuclein for: Treatment of multiple system atrophy
Date of designation: 20/05/2021, Positive, Last updated: 17/03/2022 -
List item
Orphan designation: 2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride for: Treatment of fragile X syndrome
Date of designation: 20/05/2021, Positive, Last updated: 17/03/2022 -
List item
Orphan designation: Adeno-associated viral vector serotype 2.5T encoding the human cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain for: Treatment of cystic fibrosis
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: 6-Amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamide for: Treatment of glioma
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one for: Treatment of hyperphenylalaninemia
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: Trehalose for: Treatment of amyotrophic lateral sclerosis
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: Synthetic 2′-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a triantennary cluster of N-acetyl galactosamine sugars targeting transmembrane protease, serine 6 mRNA for: Treatment of beta thalassaemia intermedia and major
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: melatonin for: Treatment of retinitis pigmentosa
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: Autologous mobilised peripheral blood-derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene for: Treatment of X-linked severe combined immunodeficiency
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: Adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene for: Treatment of Leber's congenital amaurosis
Date of designation: 20/05/2021, Positive, Last updated: 18/03/2022 -
List item
Orphan designation: Dantrolene sodium, hemiheptahydrate for: Treatment of malignant hyperthermia
Date of designation: 20/05/2021, Positive, Last updated: 24/03/2022 -
List item
List of medicines under additional monitoring (updated)
Last updated: 30/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 July 2022
European Medicines Agency, Amsterdam, the Netherlands, from 04/07/2022 to 07/07/2022, Last updated: 31/03/2023